Research programme: HIV fusion inhibitors - Ocera Therapeutics/Trimeris
Latest Information Update: 14 Dec 2017
At a glance
- Originator Tranzyme Pharma
- Developer Tranzyme Pharma; Trimeris
- Class Small molecules
- Mechanism of Action HIV fusion inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 11 Dec 2017 Ocera Therapeutics has been acquired by Mallinckrodt
- 19 Mar 2008 Discontinued - Preclinical for HIV infections in Canada (unspecified route)
- 19 Mar 2008 Discontinued - Preclinical for HIV infections in USA (unspecified route)